Whitman Walker Health CRS

1701 14th Street, N.W.
Washington D.C., 20009
United States of America

https://www.whitman-walker.org/research-program

Anna Wimpelberg
awimpelberg@whitman-walker.org
202-797-3589

Sarah Henn
shenn@whitman-walker.org
202-745-6172

• A5128: US Genomic Sampling
• A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
• A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV 
• A5332: REPRIEVE Trial
• A5345: HIV Rebound & Control Biomarkers
• A5354: Early ART in Acute HIV
• A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants
• A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
• A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
• A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
• A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B